公开(公告)号：EP2703005A1

公开(公告)日：2014-03-05

申请号：EP12182994.9

申请日：2012-09-04

申请人： Università Degli Studi Di Torino ,  Fondazione Piemontese per la Ricerca sul Cancro-ONLUS

发明人： Bussolino, Federico. ,  Marchio, Serena.

IPC分类号： A61K38/17 ,  C12N15/00 ,  G01N33/00 ,  A61P35/04

CPC分类号： A61K38/177 ,  A61K38/1777 ,  C07K7/06 ,  C07K14/705 ,  C07K14/70546 ,  G01N33/57407 ,  G01N33/57419 ,  G01N2333/705 ,  G01N2333/70546 ,  G01N2500/00 ,  G01N2800/52

摘要： In one aspect, the invention relates to an inhibitor of the α 6 integrin/E-cadherin molecular complex for use as a medicament, in particular for the prevention or/and treatment of metastases of a primary cancer disease and a pharmaceutical composition or kit comprising as an active agent at least one of the inhibitors. In a further embodiment, the present invention relates to a method for determining the prognosis of metastatic homing of a primary cancer disease, in particular the aggressiveness of the metastatic potential of a primary cancer disease.

摘要翻译： 一方面，本发明涉及用作药物的±6整联蛋白/ E-钙粘蛋白分子复合物的抑制剂，特别是用于预防或/和治疗原发性癌症疾病的转移和药物组合物或试剂盒，其包含 作为至少一种抑制剂的活性剂。 在另一个实施方案中，本发明涉及一种用于确定原发性癌症疾病的转移归巢预后的方法，特别是原发性癌症疾病的转移潜力的侵袭性。